Fig. 1: C16 in combination with Ang-1 treatment improved the functional impairment.
a–d Measurements of total traveled distance (a: mice; b: rats) and mean velocity (c: mice; d: rats) of each group in the open field test. The motor function assessment revealed neurological disabilities in model animals. a–f C16 or Ang-1 alone ameliorated functional impairment in PD animals, while the combination of C16 and Ang-1 exhibited more potent therapeutic effects including the reduction in the mean velocity of both animal models in the open field test, decreased distance traveled in 6-OHDA-treated rats, and increased time on the rotarod test device in MPTP-treated mice. g, h PD animals showed an impaired ability to recognize objects, while treatment with C16 or Ang-1, and especially with C16 plus Ang-1 alleviated memory issues. a p < 0.05 versus the normal control group; b p < 0.05 versus the p < 0.05 versus the MPTP/6-OHDA insult group; c p < 0.05 versus the C16-treated group.; d p < 0.05 versus the Ang-1-treated group. C16, peptide (KAFDITYVRLKF) that can selectively bind integrin ανβ3; Ang-1 angiopoietin-1; PD, Parkinson’s disease.
